[HTML][HTML] SARS vaccine development
Developing effective and safe vaccines is urgently needed to prevent infection by severe
acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV). The inactivated …
acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV). The inactivated …
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
The spike protein (S) of SARS coronavirus (SARS-CoV) attaches the virus to its cellular
receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain …
receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain …
Development of antiviral therapy for severe acute respiratory syndrome
J Cinatl Jr, M Michaelis, G Hoever, W Preiser… - Antiviral research, 2005 - Elsevier
A new disease, the severe acute respiratory distress syndrome (SARS), caused by the
SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread …
SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread …
A human SARS-CoV neutralizing antibody against epitope on S2 protein
J Duan, X Yan, X Guo, W Cao, W Han, C Qi… - Biochemical and …, 2005 - Elsevier
An immune antibody phage-display library was constructed from B cells of SARS
convalescent patients. More than 80 clones were selected from the library by using the …
convalescent patients. More than 80 clones were selected from the library by using the …
The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries
RA Kramer, WE Marissen, J Goudsmit… - European journal of …, 2005 - Wiley Online Library
Antibody phage display technology was used to identify human monoclonal antibodies that
neutralize rabies virus (RV). A phage repertoire was constructed using antibody genes …
neutralize rabies virus (RV). A phage repertoire was constructed using antibody genes …
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major …
CE Yi, L Ba, L Zhang, DD Ho, Z Chen - Journal of virology, 2005 - Am Soc Microbiol
Neutralizing antibodies (NAbs) against severe acute respiratory syndrome (SARS)
coronavirus (SARS-CoV) spike (S) glycoprotein confer protection to animals experimentally …
coronavirus (SARS-CoV) spike (S) glycoprotein confer protection to animals experimentally …
SARS: understanding the virus and development of rational therapy
K Stadler, R Rappuoli - Current Molecular Medicine, 2005 - ingentaconnect.com
In late 2002 a new disease, severe atypical respiratory syndrome (SARS), emerged in
China. A hitherto unknown animal coronavirus (CoV) that had crossed the species barrier …
China. A hitherto unknown animal coronavirus (CoV) that had crossed the species barrier …
[PDF][PDF] Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS
MY Zhang, V Choudhry, X Xiao, DS Dimitrov - Curr Opin Mol Ther, 2005 - researchgate.net
Polyclonal antibodies have a century-old history of being effective against some viruses and,
recently, monoclonal antibodies (mAbs) have also shown some clinical success. Human …
recently, monoclonal antibodies (mAbs) have also shown some clinical success. Human …
SARS-CoV genome polymorphism: a bioinformatics study
GM Pavlović-Lažetić, NS Mitić… - Genomics …, 2005 - academic.oup.com
A dataset of 103 SARS-CoV isolates (101 human patients and 2 palm civets) was
investigated on different aspects of genome polymorphism and isolate classification. The …
investigated on different aspects of genome polymorphism and isolate classification. The …
噬菌体显示库在病毒研究中的应用
孙婷， 赵丽艳， 李才 - 吉林大学学报(医学版), 2005 - xuebao.jlu.edu.cn
噬菌体显示技术近年来在分子克隆领域应用极为广泛, 其是将蛋白质表达于噬菌体表面,
将病毒的抗原或抗体表达于噬菌体表面, 或从噬菌体随机肽库中筛选出某种病毒的抗原或抗体表 …
将病毒的抗原或抗体表达于噬菌体表面, 或从噬菌体随机肽库中筛选出某种病毒的抗原或抗体表 …